Get the Stockscreener App
30.76
0.38%
0.1268
Akero Therapeutics Inc stock is traded at $30.76, with a volume of 41,884.
It is up +0.38% in the last 24 hours and down -0.48% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$30.64
Open:
$30.88
24h Volume:
41,884
Relative Volume:
0.08
Market Cap:
$2.14B
Revenue:
-
Net Income/Loss:
$-179.27M
P/E Ratio:
-12.02
EPS:
-2.56
Net Cash Flow:
$-155.88M
1W Performance:
+3.33%
1M Performance:
-0.48%
6M Performance:
+51.93%
1Y Performance:
+91.36%
1-Day Range:
$29.97
$30.88
1-Week Range:
$27.05
$31.60
52-Week Range:
$15.32
$37.00
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AKRO | 30.79 | 2.14B | 0 | -179.27M | -155.88M | -2.56 |
| VRTX | 448.33 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.13 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.33 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
How To Trade (AKRO) - Stock Traders Daily
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Scrip
Akero Therapeutics' chief development officer sells $251,274 in stock - Investing.com
Citigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Inventiva Getting Back On Track In NASH Development - Citeline News & Insights
Akero a new buy at Citi on liver disease asset - Seeking Alpha
HC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat
Citigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat
Citi bullish on Akero stock as efruxifermin targets MASH market leadership - Investing.com Canada
Akero Therapeutics (NASDAQ:AKRO) Shares Down 6.4%What's Next? - MarketBeat
Akero reports positive EFX trial results for liver disease By Investing.com - Investing.com Canada
Akero reports positive EFX trial results for liver disease - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Simplify Asset Management Inc. - MarketBeat
Akero Therapeutics to Showcase New Analyses of Phase 2b - GlobeNewswire
Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 - Marketscreener.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Decline in Short Interest - MarketBeat
Janus Henderson Group PLC's Strategic Acquisition of Akero Thera - GuruFocus.com
What is HC Wainwright's Estimate for AKRO FY2024 Earnings? - MarketBeat
RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc - GuruFocus.com
Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Akero Therapeutics to Present at Jefferies London Healthcare Conference | AKRO Stock News - StockTitan
ALKEON CAPITAL MANAGEMENT LLC Reduces Stake in Akero Therapeutics Inc - GuruFocus.com
FY2028 EPS Forecast for Akero Therapeutics Raised by Analyst - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright - Defense World
Akero Therapeutics Advances in MASH Treatment Trials - Yahoo Finance
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of i - Defense World
(AKRO) Trading Advice - Stock Traders Daily
Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat
Akero Therapeutics executive sells $351,890 in stock - Investing.com
Akero Therapeutics executive sells $351,890 in stock By Investing.com - Investing.com Australia
Wellington Management Group LLP's Strategic Acquisition of Akero Therapeutics Shares - GuruFocus.com
Akero Therapeutics Inc (AKRO) Quarterly 10-Q Report - Quartzy
Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Akero Reports $787M Cash Reserve, Advances Phase 3 MASH Drug Trials Despite Higher Costs | AKRO Stock News - StockTitan
Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $43.20 - MarketBeat
Akero Therapeutics COO sells $1.6 million in stock By Investing.com - Investing.com South Africa
Akero Therapeutics COO sells $1.6 million in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 Shares - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com
abrdn plc Trims Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat
Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com India
Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com Australia
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat
Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan
Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):